Overview
Takeda Pharmaceutical Co., Ltd. is a Japan-based, research-driven biopharmaceutical company that develops, produces and commercializes medicines worldwide. Its business spans gastrointestinal conditions, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Founded in Osaka in 1781, Takeda has its global headquarters in Tokyo.[1][2]
Takeda states that its purpose is to contribute to better health for people and a brighter future for the world by discovering and delivering life-transforming treatments. It operates in approximately 80 countries and regions. For the fiscal year ended March 31, 2025, it reported revenue of ¥4.58 trillion and had 47,455 employees.[3][4][5] [1][2][3][4][5]
Products & services
Takeda’s gastrointestinal products include ENTYVIO (vedolizumab), a treatment for moderate-to-severe ulcerative colitis and Crohn’s disease, and EOHILIA (budesonide oral suspension), a corticosteroid treatment for eosinophilic esophagitis. Its rare-disease medicines include TAKHZYRO (lanadelumab), which prevents hereditary angioedema attacks, and LIVTENCITY (maribavir), which treats refractory cytomegalovirus infection or disease after transplantation.[6][7][8][9]
Takeda’s plasma-derived immunoglobulin products include GAMMAGARD LIQUID/KIOVIG for antibody replacement, HYQVIA, a subcutaneous immunoglobulin treatment, and CUVITRU, a 20% subcutaneous immunoglobulin solution. Its oncology products include ADCETRIS for certain lymphomas, oral proteasome inhibitor NINLARO for multiple myeloma, and FRUZAQLA for previously treated metastatic colorectal cancer. The portfolio also includes VYVANSE/ELVANSE for attention-deficit/hyperactivity disorder and adult binge-eating disorder, and QDENGA, a live-attenuated dengue vaccine.[10][11][12][13][14][15][16][17]
In the fiscal year ended March 2025, ENTYVIO generated ¥914.1 billion, approximately 20% of Takeda’s revenue. GAMMAGARD LIQUID/KIOVIG, HYQVIA and CUVITRU generated ¥757.8 billion *combined*, approximately 17%; TAKHZYRO generated ¥223.2 billion, approximately 5%.[6][18][8][19] [6][7][8][9][10][11][12][13][14][15][16][17][18][19]
Geographic presence
Takeda has its global headquarters in Tokyo and its head office in Osaka. Its operations span approximately 80 countries and regions. Listed major facilities include production and research sites in Japan, production sites in the United States and several European countries, and production in Singapore; the listed U.S. research site is in Cambridge, Massachusetts.[20][21]
In the fiscal year ended March 31, 2025, Takeda reported ¥4,581.6 billion in revenue. The United States accounted for ¥2,379.7 billion (about 52%), Europe and Canada together ¥1,055.3 billion (23%), and Japan ¥418.5 billion (9%). Other reported markets included Latin America (¥235.8 billion), China (¥191.7 billion), Asia excluding Japan and China (¥99.4 billion), and Russia/CIS (¥72.4 billion).[22] At March 31, 2025, Takeda reported 47,455 employees, including 20,955 in the United States, 14,012 in Europe and Canada, 4,932 in Japan, and 7,555 in other locations.[5] [20][21][22][22][22][22][22][22][22][22][5][5][5][5][5]
Business segments
Takeda reports a single operating segment: pharmaceutical products, encompassing research, development, manufacturing, marketing and out-licensing. Its therapeutic business areas are a breakdown of revenue, not separate reportable operating segments.[23]
For the fiscal year ended March 2025, Gastroenterology accounted for approximately 30% of revenue, led by treatments for inflammatory bowel disease; Plasma-Derived Therapies accounted for 23%, principally immunoglobulin and albumin products; and Rare Diseases accounted for 16%, including treatments for hereditary angioedema and hemophilia. Neuroscience contributed approximately 12%, Oncology 12%, and Vaccines 1%, including the dengue vaccine QDENGA. Other products and income made up the remaining 6%. Percentages are calculated from Takeda’s reported business-area revenue and consolidated revenue.[24][25][6][8][26][17] [23][24][25][6][8][26][17]
Company history
Takeda traces its origins to 1781, when Chobei Takeda I began selling traditional Japanese and Chinese medicines in Osaka’s Doshomachi district. The company opened its first owned manufacturing facility in Japan in 1915. Its postwar product launches included Alinamin in 1954; later pharmaceutical milestones included the Japanese launch of the acid-suppressing drug lansoprazole in 1992 and the initial U.S. approval of the diabetes drug Actos in 1999.[27][28][29][30][31]
Takeda expanded through its acquisition of the oncology company Millennium in 2008 and its acquisition of Nycomed in 2011. In 2014, its inflammatory-bowel-disease treatment Entyvio received U.S. approval. Christophe Weber became chief executive officer in 2015, and Takeda completed its acquisition of Shire in 2019.[32][33][34][35][36] [27][28][29][30][31][32][33][34][35][36]
Sources
- TAKEDA PHARMACEUTICAL CO LTD — Full financial report (2025 Y)
- TAKEDA PHARMACEUTICAL CO LTD — Full financial report (2024 Y)[23]
- www.takeda.com[27]
- www.takeda.com[28]
- alinamin-pharma.co.jp[29]
- takepron-s.jp[30]
- content.takeda.com[31]
- www.sec.gov[32]
- www.takeda.com[33]
- www.takeda.com[34]
- www.takeda.com[35]
- www.takeda.com[36]
Continue your research
From company context to financial detail.
Explore original sources and worldwide fundamental financial data and intelligence with Finbar.
Explore TAKEDA PHARMACEUTICAL CO LTD in Finbar ↗